Press Release
December 18, 2025
New York, NY & Basel, Switzerland — Dec 18 2025
dsm-firmenich, a global leader in suncare innovation, and The Skin Cancer Foundation, America’s leading nonprofit dedicated to skin cancer prevention, celebrate their ongoing partnership in the fight against skin cancer through the acclaimed Destination Healthy Skin program.
Destination Healthy Skin: Expanding Access, Saving Lives
The Skin Cancer Foundation’s Destination Healthy Skin program is a national mobile initiative that brings free, full-body skin cancer screenings and education directly to communities across the United States. Since its launch, the program’s volunteer dermatologists have provided nearly 33,000 free skin cancer screenings, identifying over 13,000 potential skin cancers and precancers, including more than 615 suspected melanomas. The program has distributed educational materials and sun protection products to over 109,000 people, reaching urban, suburban, and rural areas—including many “derm deserts” where access to dermatologists is limited. In 2025 alone, the program visited 17 cities, hosted 27 events, and performed over 1,300 screenings, with about 65% of participants receiving their very first skin cancer exam.
dsm-firmenich is honoured to have supported Destination Healthy Skin for multiple consecutive years, ensuring this life-saving program continues to reach and serve thousands across the country. This partnership reflects a shared commitment to public health, early detection, and expanding access to sun protection and education for all Americans.
dsm-firmenich: Innovation for Prevention and Expanding Choices
dsm-firmenich is proud to announce that PARSOL® Shield, the next-generation sunscreen active ingredient, is in the final stages of FDA review for U.S. approval, which is expected by June 2026. Already approved and trusted across Europe, Australia, and Asia, PARSOL® Shield is poised to become the first new sunscreen active added to the U.S. OTC monograph in more than 25 years, setting a new standard for sun protection and supporting efforts to prevent skin cancer. Parand Salmassinia, President of Beauty & Care at dsm-firmenich, said: “A successful approval by the FDA, marks a monumental step in dsm-firmenich’s commitment to driving innovation in sun care, consumer health, and sustainability. PARSOL® Shield has been safely used worldwide for over 20 years, and we are proud to lead the introduction of this proven technology to U.S. consumers. If approved, it will elevate the standard of sun protection and play a vital role in public health and skin cancer prevention by expanding consumer choices.”
The Skin Cancer Foundation: Advocacy and Mission
Skin cancer is the most common cancer in the United States, with more than two people dying every hour and one in five Americans developing skin cancer by age 70. The Skin Cancer Foundation’s mission is to save and improve lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. Deborah S. Sarnoff, MD, President of The Skin Cancer Foundation, said: “Skin cancer is both highly preventable and highly treatable when detected early. The Foundation is dedicated to saving lives through education, research, and advocating for access to effective solutions. Expanding consumer choices in sun protection is essential to closing the gap in compliance and making daily sun protection effortless for all Americans. Together, we can save lives and reduce the impact of this disease.”
Empowering Daily Protection
Both organizations encourage Americans to make daily sun protection a priority, schedule regular skin exams and choose sunscreen solutions that fit seamlessly into everyday routines.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion.
beautycare.communications@dsm-firmenich.com
LinkedIn | X | Instagram | Facebook
About the Skin Cancer Foundation
The Skin Cancer Foundation (SCF), a 501(c)(3) nonprofit organization, saves and improves lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. The Foundation delivers public education programs, provides patients with guidance and reassurance, engages medical professionals, awards research grants and leads advocacy campaigns that call for policy changes. As a service to consumers, SCF grants its industry-recognized Seal of Recommendation to products that meet its criteria for safe and effective sun protection. SCF also operates Destination Healthy Skin, a program that works with local dermatologists in communities around the U.S. to provide free skin cancer screenings to those in need. Since its inception in 1979, the Foundation has recommended regular skin exams and following a complete sun protection strategy that includes seeking shade, using sunscreen daily and covering up with clothing, hats and sunglasses.
Press@SkinCancer.org
SkinCancer.org
Skin Cancer Foundation’s Destination Healthy Skin
Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.